Full Press Release Details
Monte Rosa Therapeutics to Present at 5th Annual Targeted Protein Degradation Summit and 34th EORTC-NCI-AACR Symposium.
GLUE
Monte Rosa Therapeutics to Present at 5th Annual Targeted Protein Degradation Summit and 34th EORTC-NCI-AACR Symposium
Key Takeaway: Monte Rosa Therapeutics to Present at 5th Annual Targeted Protein Degradation Summit and 34th EORTC-NCI-AACR Symposium
Price reaction · baseline $7.58 (2022-10-19 close) · hit after-hours · 1 other GLUE headline(s) in the window, move may be shared
day 0 close · peak
-2.5%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+67%
120-day peak, hindsight
Typical move
13.3%
average across 9 past catalysts
Cash runway
~41 mo
Minimal dilution risk
Lead asset
MRT-2359
Phase 2 · Castration-Resistant Prostate Cancer (CRPC)